A Deletion Variant of Human Factor VIII Displaying Low Immunogenicity in a Murine Model of Hemophilia A
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262412093 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Erika de Simone Molina und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cell and Molecular Therapy NUCEL Group, School of Medicine, University of São Paulo, São Paulo 02146-903, SP, Brazil. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Sequence Deletion. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeicoamento de Pessoal de Nível Superior, National Council for Scientific and Technological Development, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
The therapeutic clotting factor VIII (FVIII) is known for its particular immunogenicity, with nearly 30% of hemophilic patients developing neutralizing antibodies against the infused protein. The root cause of this immunogenicity is still not well understood, but intrinsic factors, such as FVIII byproducts, have been linked to the immunological response elicited. Bioengineering of the FVIII molecule has been improving its recombinant (rhFVIII) production in many aspects, mainly enhancing its expression and stability. Assessment of immunogenicity for novel recombinant isoforms is crucial for further development and scaling-up processes, particularly due to the unpredictable antigenic properties and their impact on neutralizing antibody formation. In the present study, we describe a bioengineered human recombinant FVIII (rhFVIII-H6A), which induces lower immunogenicity in a murine model of hemophilia A. The rhFVIII-H6A product is characterized by a B-domain-deleted heavy chain (HCh), with the C-terminal of the B-domain fused to the light chain (BΔ-LCh). Compared to plasma-derived FVIII (pdFVIII) and rhFVIII reference products, treating hemophilic mice with rhFVIII-H6A induced lower levels of anti-FVIII antibody formation, including those with inhibitory neutralizing activity, while no difference was observed in the functional activity of rhFVIII-H6A in reverting the in vivo hemophilia phenotype. In addition, our results indicate that deleting the major part of the B-domain from the HCh might lower the immunogenicity of novel rhFVIII products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell and Molecular Therapy NUCEL Group, School of Medicine, University of São Paulo, São Paulo 02146-903, SP, Brazil.
- Biochemistry Department, Chemistry Institute, University of São Paulo, São Paulo 05508-000, SP, Brazil.
ORCID-Profile: Erika de Simone Molina, Theri Leica Degaki, Mari Cleide Sogayar, Marcos Angelo Almeida Demasi
Förderung
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- National Council for Scientific and Technological Development
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Brazilian Higher Education Personnel Improvement Coordination
- National Council for Scientific and Technological Development (CNPq) to INCT-REGENERA
- São Paulo State Research Foundation—FAPESP, Thematic
Zitieren
APA
Molina, E. S., Degaki, T. L., Sogayar, M. C., & Demasi, M. A. A. (2025). A Deletion Variant of Human Factor VIII Displaying Low Immunogenicity in a Murine Model of Hemophilia A. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262412093
Vancouver
Molina ES, Degaki TL, Sogayar MC, Demasi MAA. A Deletion Variant of Human Factor VIII Displaying Low Immunogenicity in a Murine Model of Hemophilia A. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262412093
BibTeX
@article{Molina2025,
author = {Molina, Erika de Simone and Degaki, Theri Leica and Sogayar, Mari Cleide and Demasi, Marcos Angelo Almeida},
title = {A Deletion Variant of Human Factor VIII Displaying Low Immunogenicity in a Murine Model of Hemophilia A},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262412093}
}
EUVIMED